Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Spyre Therapeutics (SYRE) Return on Equity (2016 - 2025)

Spyre Therapeutics' Return on Equity history spans 10 years, with the latest figure at 0.27% for Q4 2025.

  • For Q4 2025, Return on Equity rose 23.0% year-over-year to 0.27%; the TTM value through Dec 2025 reached 0.27%, up 23.0%, while the annual FY2025 figure was 0.25%, 34.0% up from the prior year.
  • Return on Equity reached 0.27% in Q4 2025 per SYRE's latest filing, up from 0.33% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 11.04% in Q4 2023 to a low of 2.17% in Q1 2024.
  • Average Return on Equity over 5 years is 0.05%, with a median of 0.61% recorded in 2021.
  • Peak YoY movement for Return on Equity: surged 1246bps in 2023, then crashed -1153bps in 2024.
  • A 5-year view of Return on Equity shows it stood at 0.71% in 2021, then crashed by -101bps to 1.42% in 2022, then soared by 876bps to 11.04% in 2023, then crashed by -104bps to 0.49% in 2024, then surged by 46bps to 0.27% in 2025.
  • Per Business Quant, the three most recent readings for SYRE's Return on Equity are 0.27% (Q4 2025), 0.33% (Q3 2025), and 0.44% (Q2 2025).